ebola
viru
ebov
nonseg
negativesens
rna
viru
belong
ebolaviru
genu
famili
filovirida
virus
highli
pathogen
caus
ebola
viru
diseas
evd
previous
refer
ebola
hemorrhag
fever
case
fatal
rate
feldmann
geisbert
feldmann
kiley
africa
experienc
largest
ebov
outbreak
histori
result
case
death
coltart
et
al
alarmingli
recent
ebovkivu
outbreak
democrat
republ
congo
drc
report
confirm
probabl
case
evd
death
octob
current
show
sign
abat
http
current
approv
vaccin
therapeut
prevent
treat
evd
fact
combin
unpreced
outbreak
recent
year
underscor
urgent
need
develop
wide
varieti
effect
treatment
strategi
current
armamentarium
treatment
option
ebov
primarili
consist
small
molecul
immunotherapeut
edward
basler
king
et
al
report
small
molecul
demonstr
antiebov
activ
nucleosid
analog
favipriravir
shown
antiebov
activ
vivo
infect
model
bixler
et
al
warren
et
al
warren
et
al
similarli
numer
report
demonstr
monoclon
antibodi
mab
effect
inhibit
infect
brannan
et
al
furuyama
et
al
howel
et
al
king
et
al
marzi
et
al
pettitt
et
al
qiu
et
al
audet
et
al
mab
target
ebov
glycoprotein
gp
act
attach
factor
bind
host
receptor
neimannpick
mediat
viralhost
cell
membran
fusion
within
endosom
compart
davey
et
al
carett
et
al
cote
et
al
hunt
et
al
prior
receptor
engag
gp
cleav
host
cathepsin
cat
b
l
chandran
et
al
schornberg
et
al
cleavag
gp
catb
requir
bind
subsequ
endosom
fusion
miller
et
al
result
target
gp
endosom
process
receptor
bind
serv
effect
method
ebov
inhibit
inde
inhibitor
catbl
blockad
bind
shown
efficaci
ebov
infect
carett
et
al
chandran
et
al
elshabrawi
et
al
herbert
et
al
schornberg
et
al
zhang
et
al
antimicrobi
peptid
amp
also
call
host
defens
peptid
serv
essenti
compon
innat
immun
system
part
owe
pleiotrop
function
microbi
kill
inflamm
wound
heal
nakatsuji
gallo
two
major
amp
famili
mammalian
cell
defensin
cation
cathelicidin
peptid
ganz
zanetti
et
al
although
multipl
defensin
gene
one
known
cathelicidin
gene
human
lehrer
ganz
sorensen
et
al
human
cathelicidin
abundantli
express
neutrophil
monocyt
epitheli
cell
skin
mucos
membran
agerberth
et
al
sorensen
et
al
store
inact
precursor
upon
stimul
process
gener
activ
peptid
sorensen
et
al
interestingli
besid
broad
antibacteri
properti
also
inhibit
sever
virus
includ
influenza
viru
human
rhinoviru
human
adenoviru
human
immunodefici
viru
bergman
et
al
curri
et
al
uchio
et
al
sousa
et
al
recent
demonstr
amp
inhibit
zika
viru
infect
although
mechan
well
defin
et
al
nevertheless
studi
suggest
amp
serv
viabl
antivir
therapeut
present
studi
show
human
particular
two
engin
variant
function
inhibitor
ebov
infect
amp
known
direct
indirect
antimicrobi
effect
therefor
explor
mechan
action
found
amp
impair
earli
event
ebov
infect
effect
viru
replic
analysi
reveal
amp
impair
catbmedi
cleavag
ebov
gp
taken
togeth
data
demonstr
engin
amp
potent
inhibitor
ebov
entri
sinc
ebov
highli
lethal
agent
ebovgp
pseudotyp
virus
base
attenu
vector
wide
use
research
laboratori
use
recombin
vesicular
stomat
viru
rvsv
express
ebovgp
green
fluoresc
protein
rvsvebovgpgfp
short
vsvegp
experiment
system
test
effect
amp
ebovgpmedi
infect
initi
screen
amp
includ
parent
human
engin
variant
found
two
engin
variant
peptid
short
potent
inhibit
vsvegp
infect
data
shown
therefor
decid
focu
two
peptid
relev
control
peptid
studi
list
figur
parent
peptid
includ
baselin
control
peptid
contain
nativ
sequenc
respect
deriv
major
antimicrobi
region
wang
et
al
peptid
engin
three
dform
amino
acid
two
biphenylalanin
base
sequenc
novel
peptid
engin
dform
amino
acid
ident
sequenc
peptid
inact
deriv
amino
acid
serv
neg
control
hela
cell
infect
vsvegp
virus
togeth
individu
amp
mm
ebov
neutral
mab
posit
control
h
post
infect
cell
harvest
flow
cytometri
analysi
determin
percentag
cell
posit
gfp
measur
vsvegp
infect
parent
engin
amp
except
neg
control
display
differ
degre
inhibitori
effect
vsvegp
infect
figur
peptid
potent
inhibit
vsvegp
infect
inhibit
mm
wherea
peptid
led
inhibit
condit
figur
peptid
show
dosedepend
inhibit
vsvegp
infect
hela
cell
figur
human
macrophag
primari
target
natur
ebov
infect
next
examin
whether
amp
inhibit
vsvegp
infect
human
primari
macrophag
bray
geisbert
gupta
et
al
monocyt
freshli
purifi
human
blood
sampl
differenti
macrophag
treatment
macrophagecolonystimul
factor
mcsf
murray
et
al
macrophag
infect
vsvegp
togeth
mab
amp
similar
result
hela
cell
amp
except
neg
control
display
dosedepend
inhibit
vsvegp
infect
macrophag
figur
peptid
potent
almost
complet
inhibit
vsvegp
infect
macrophag
mm
figur
next
determin
b
amp
inhibit
pseudoebov
vsvegp
infect
hela
cell
dosedepend
manner
vsvegp
virus
ad
hela
cell
togeth
monoclon
antibodi
mgml
individu
amp
mm
h
cultur
hela
cell
harvest
flow
cytometri
analysi
measur
viral
infect
p
twoway
anova
test
c
amp
inhibit
pseudoebov
vsvegp
infect
human
primari
macrophag
human
monocyt
freshli
purifi
blood
differenti
macrophag
cultur
cell
media
contain
mcsf
macrophag
infect
vsvegp
presenc
mab
mgml
amp
mm
cell
analyz
flow
cytometri
h
post
infect
p
p
twoway
anova
test
summari
efficaci
toxic
amp
hela
cell
human
primari
macrophag
cell
infect
vsvegp
togeth
amp
differ
concentr
rang
mm
analyz
flow
cytometri
h
post
infect
evalu
ic
half
maxim
inhibitori
concentr
measur
cytotox
cell
treat
alon
amp
differ
concentr
h
cell
viabil
measur
mtt
cell
prolifer
assay
determin
tc
half
maxim
toxic
concentr
halfmaxim
concentr
inhibit
ic
halfmaxim
concentr
cell
toxic
tc
amp
hela
cell
primari
macrophag
amp
display
lower
ic
concentr
hela
cell
macrophag
although
also
display
slightli
lower
tc
concentr
hela
cell
macrophag
figur
among
parent
engin
variant
peptid
favor
therapeut
window
hela
cell
primari
macrophag
ic
mm
tc
mm
hela
cell
ic
mm
tc
mm
macrophag
peptid
also
favor
therapeut
window
ic
mm
tc
mm
hela
cell
ic
mm
tc
mm
macrophag
figur
also
examin
effect
amp
vsvegp
infect
vero
cell
cell
line
commonli
use
propag
virus
analyz
viru
infect
similarli
parent
engin
variant
except
neg
control
display
dosedepend
inhibit
vsvegp
infect
vero
cell
figur
agreement
find
hela
cell
primari
macrophag
potent
peptid
inhibit
vsvegp
infect
vero
cell
peptid
almost
complet
inhibit
vsvegp
infect
concentr
mm
vero
cell
figur
taken
togeth
data
show
engin
variant
peptid
potent
inhibitor
ebov
pseudovirion
infect
hela
vero
cell
well
human
primari
macrophag
given
observ
potenc
amp
within
surrog
ebov
system
next
test
whether
amp
similar
effect
wildtyp
wt
ebov
infect
hela
cell
preincub
amp
differ
concentr
h
infect
ebovkiwit
h
post
infect
cell
fix
permeabil
immunostain
antiebov
gp
antibodi
follow
fluorescenceconjug
secondari
antibodi
identifi
infect
cell
agreement
ebov
pseudovirion
studi
engin
peptid
display
much
higher
potenc
block
infect
wt
ebov
peptid
contain
lamino
acid
figur
peptid
ic
mm
respect
wherea
ic
mm
figur
interestingli
amp
significantli
affect
marburg
viru
marv
infect
condit
demonstr
specif
amp
inhibit
ebov
infect
figur
inhibitori
effect
engin
amp
wt
ebov
infect
support
find
engin
amp
may
new
class
antiebov
countermeasur
highlight
consist
wt
ebov
surrog
system
determin
potenti
mechan
respons
inhibitori
effect
amp
ebov
infect
next
examin
whether
amp
target
ebov
cell
entri
compar
effect
pretreat
delay
amp
treatment
cell
prior
viral
infect
previous
observ
figur
amp
reduc
vsvegp
infect
human
primari
macrophag
inhibit
mm
ad
time
infect
figur
pretreat
macrophag
h
prior
viral
infect
block
vsvegp
infect
similar
efficaci
figur
howev
delay
treatment
macrophag
peptid
result
timedepend
reduct
effect
approxim
inhibit
ad
h
post
infect
complet
loss
inhibit
ad
h
post
infect
figur
data
suggest
engin
amp
peptid
may
target
earli
cell
entri
stage
ebov
infect
similar
result
observ
vero
cell
figur
next
use
ebola
viruslik
particl
vlp
directli
test
effect
amp
ebov
cell
entri
ebola
vlp
produc
coexpress
ebov
matrix
protein
fuse
blactamas
ebov
gp
vlp
possess
structur
biochem
composit
similar
wt
ebov
unlik
wt
viru
lack
genet
materi
viru
replic
activ
cytoplasm
blactamas
thu
repres
rel
level
product
cell
entri
ebola
vlp
vero
cell
preincub
amp
cathepsin
b
catb
specif
inhibitor
posit
control
follow
ebola
vlp
infect
catb
inhibitor
peptid
display
dosedepend
inhibit
cytoplasm
blactamas
activ
provid
direct
evid
engin
amp
inhibit
product
ebov
cell
entri
figur
enter
cytoplasm
ebov
undergo
replic
amplifi
genet
materi
order
produc
progeni
virion
absenc
wt
viru
replic
studi
use
ebov
minigenom
system
cressey
et
al
next
examin
effect
amp
ebov
replic
use
system
ebov
minigenom
plasmid
encod
firefli
luciferas
report
gene
flank
leader
trailer
sequenc
ebov
genom
cotransfect
hela
cell
four
support
plasmid
encod
ebov
replic
complex
compon
np
l
plasmid
encod
renilla
luciferas
normal
transfect
effici
ratio
firefli
renilla
luciferas
repres
rel
level
ebov
minigenom
replic
none
test
amp
mm
led
signific
chang
ratio
firefli
renilla
luciferas
wherea
posit
control
ribavirin
significantli
reduc
ebola
vlp
produc
coexpress
ebov
matrix
protein
fuse
blactamas
ebov
gp
vero
cell
pretreat
amp
mm
cathepsin
b
inhibitor
methyl
ester
mm
posit
control
h
c
infect
ebola
vlp
h
post
infect
membraneperm
blactamas
substrat
ad
cultur
incub
h
room
temperatur
releas
blactamas
vlp
cytoplasm
cell
result
success
process
cell
entri
vlp
endosom
measur
fluoresc
emiss
substrat
within
h
infect
p
p
twoway
anova
test
c
engin
amp
affect
ebov
replic
minigenom
system
ebov
minigenom
plasmid
encod
firefli
luciferas
report
gene
flank
leader
trailer
sequenc
ebov
genom
cotransfect
hela
cell
four
support
plasmid
encod
ebov
replic
complex
compon
np
l
plasmid
encod
renilla
luciferas
normal
transfect
effici
ratio
firefli
renilla
luciferas
repres
rel
level
ebov
minigenom
replic
p
oneway
anova
test
iscienc
april
ratio
figur
data
suggest
engin
variant
affect
ebov
replic
minigenom
system
collect
result
suggest
engin
variant
peptid
block
ebov
cell
entri
viral
replic
product
ebov
cell
entri
infect
requir
process
cleavag
ebovgp
cathepsin
within
endosom
therefor
next
test
whether
amp
block
catband
catlmedi
cleavag
ebovgp
catb
preincub
amp
known
catb
inhibitor
methyl
ester
posit
control
ph
buffer
addit
ebov
gp
protein
reaction
mixtur
subject
western
blot
analysi
analyz
ebov
gp
proteolyt
cleavag
expect
ebov
gp
kd
cleav
catb
gener
product
denatur
gel
figur
catb
inhibitor
test
amp
except
neg
control
effect
block
process
ebovgp
catb
figur
howev
none
test
amp
effect
process
ebovgp
catl
condit
figur
use
standard
catb
catl
substrat
next
test
whether
amp
block
intrins
activ
catb
catl
test
amp
except
neg
control
inhibit
catbmedi
cleavag
zargargamc
dosedepend
manner
figur
engin
peptid
effect
inhibit
catb
activ
among
test
peptid
ic
mm
figur
howev
none
peptid
inhibit
effect
catlmedi
cleavag
zpheargamc
figur
data
demonstr
engin
amp
directli
inhibit
intrins
enzymat
activ
catb
catl
notabl
parent
deriv
efficaci
similar
engin
variant
inhibit
catbmedi
ebov
gp
egp
cleavag
vitro
howev
efficaci
inhibit
ebov
infect
cell
much
lower
variant
contain
damino
acid
postul
amp
compos
lamino
acid
suscept
degrad
proteolyt
enzym
insid
cell
thu
reduc
avail
block
catb
vivo
test
hypothesi
examin
whether
amp
suscept
cat
cleavag
vitro
reaction
cat
use
abund
cathepsin
endosomelysosom
macrophag
shown
excel
substrat
cat
shi
et
al
andrault
et
al
amp
compos
lamino
acid
complet
degrad
cat
treatment
reaction
wherea
amp
contain
damino
acid
resist
cat
cleavag
figur
data
indic
amp
compos
lamino
acid
suscept
degrad
cat
upon
enter
cell
hypothes
blockag
cat
may
stabil
amp
insid
cell
thu
make
avail
inhibit
catbmedi
ebov
entri
test
hypothesi
vero
cell
pretreat
cat
inhibitor
h
follow
addit
amp
vsvegp
cat
inhibitor
treatment
significantli
improv
efficaci
inhibit
vsvegp
infect
figur
notabl
cat
inhibitor
also
improv
efficaci
cat
inhibitor
treatment
alon
result
inhibit
vsvegp
infect
like
due
known
abil
inhibitor
crossinhibit
catb
collect
data
suggest
amp
suscept
enzymat
degrad
insid
cell
engin
amp
damino
acid
resist
degrad
thu
effect
inhibit
ebov
infect
report
demonstr
engin
amp
base
human
cathelicidin
inhibit
ebov
infect
mechanist
studi
reveal
amp
act
catb
inhibitor
block
endosom
process
ebov
gp
thu
prevent
viru
entri
result
identifi
engin
amp
potenti
novel
class
antiebov
therapeut
provid
addit
avenu
combat
highli
lethal
ebov
human
cathelicidin
sever
limit
therapeut
molecul
first
rel
long
amino
acid
second
rapidli
degrad
proteas
third
lose
activ
certain
condit
design
engin
aim
overcom
limit
differ
activ
region
identifi
previou
structurefunct
studi
sigurdardottir
et
al
nell
et
al
braff
et
al
nagaoka
et
al
li
et
al
chosen
templat
peptid
engin
activ
methicillinresist
staphylococcu
aureu
mrsa
among
activ
peptid
discov
previous
anoth
studi
found
three
amino
acid
extens
nterminu
increas
activ
inhibit
base
respect
design
incorpor
damino
acid
enhanc
biostabl
interestingli
found
effect
inhibit
ebov
infect
parent
deriv
peptid
previou
studi
shown
peptid
resist
chymotrypsin
bacteri
proteas
fungal
proteas
k
degrad
peptid
compos
lamino
acid
show
peptid
resist
degrad
cat
cystein
proteinas
abund
lysosom
macrophag
dendrit
cell
epitheli
cell
shi
et
al
shi
et
al
addit
pretreat
cell
cat
inhibitor
significantli
enhanc
efficaci
parent
deriv
amp
compos
lamino
acid
inhibit
ebov
infect
figur
result
suggest
import
role
cat
mediat
instabl
amp
insid
cell
previou
studi
report
excel
substrat
cat
seven
potenti
cleavag
site
andrault
et
al
therefor
anticip
target
engin
amp
elimin
cat
cleavag
site
produc
stabl
version
amp
may
display
enhanc
efficaci
inhibit
ebov
infect
vitro
studi
show
deriv
amp
inhibitor
catb
catl
use
ebov
gp
standard
substrat
enzym
result
contrast
previou
studi
claim
select
inhibitor
catl
catb
andrault
et
al
address
potenti
experiment
differ
addit
confirm
studi
result
use
two
independ
sourc
catb
catl
one
sourc
provid
cathepsin
purifi
liver
sourc
provid
cathepsin
recombin
form
case
confirmatori
experi
agre
origin
result
data
shown
commerci
avail
catband
catlspecif
inhibitor
perform
expect
assay
figur
although
endosom
cystein
proteas
requir
cell
entri
filoviru
famili
member
differ
virus
distinct
proteas
prefer
misasi
et
al
catb
requir
ebov
cell
entri
wherea
sever
studi
suggest
marv
cell
entri
requir
catb
although
clear
proteas
requir
gnirss
et
al
misasi
et
al
sanchez
agreement
studi
found
none
test
amp
significantli
inhibit
marv
infect
figur
two
damino
acidcontain
amp
display
potent
inhibit
ebov
infect
minim
inhibit
marv
infect
ic
mm
respect
futur
studi
interest
test
whether
amp
also
inhibit
infect
virus
viral
cell
entri
involv
catb
filoviru
famili
member
eg
bundibugyo
viru
misasi
et
al
middl
east
respiratori
syndrom
mer
sever
acut
respiratori
syndrom
sar
coronavirus
elshabrawi
et
al
notabl
amp
less
effici
inhibit
ebov
infect
macrophag
hela
vero
cell
figur
two
potenti
mechan
may
explain
observ
first
profession
antigenpres
cell
macrophag
like
contain
abund
proteas
cathepsin
therefor
amp
peptid
less
avail
macrophag
inhibit
viral
infect
second
known
primari
macrophag
refractori
ebov
infect
compar
tissuecultur
cell
line
ie
vero
hela
ebov
macrophag
infect
requir
higher
moi
compar
cell
line
therefor
like
increas
amount
amp
need
achiev
similar
degre
inhibit
final
note
data
consist
find
ebov
neutral
antibodi
demonstr
less
potenc
higher
ic
valu
primari
macrophag
rel
cell
line
current
promis
treatment
option
ebov
primarili
consist
nucleosid
analog
small
molecul
immunotherapi
use
neutral
antibodi
edward
basler
king
et
al
interest
test
whether
combin
use
engin
amp
therapeut
regimen
addit
efficaci
given
distinct
inhibit
mechan
involv
anticip
combin
amp
small
molecul
interfer
viral
replic
virusneutr
antibodi
improv
efficaci
ebov
summari
studi
demonstr
inhibitori
effect
engin
amp
ebov
cell
entri
futur
studi
test
therapeut
potenti
amp
wellestablish
ebov
anim
model
common
rout
ebov
infect
blood
bodi
fluid
anticip
intraven
inject
engin
amp
peptid
effect
although
topic
use
peptid
could
option
combat
ebov
infect
direct
skin
contact
anim
studi
confirm
engin
amp
novel
class
antiebov
therapeut
mechanist
studi
perform
use
ebov
surrog
system
followup
experi
use
live
viru
anim
system
need
extend
clinic
util
find
current
work
limit
singl
filoviru
member
futur
effort
test
addit
filoviru
famili
member
method
found
accompani
transpar
method
supplement
file
supplement
inform
found
onlin
http
studi
support
nebraska
univers
nu
collabor
initi
system
biolog
seed
grant
award
ks
peptid
synthesi
support
nih
grant
gw
liveviru
studi
conduct
usamriid
within
biosafeti
level
contain
opinion
interpret
conclus
recommend
author
necessarili
endors
depart
defens
us
armi
yy
perform
experi
analyz
data
contribut
manuscript
write
clc
provid
vsvegp
mab
supervis
wildtyp
ebov
marv
infect
experi
contribut
experiment
design
manuscript
write
gw
provid
antimicrobi
peptid
contribut
experiment
design
manuscript
write
mjm
kk
jpt
yl
js
akz
lgl
perform
experi
report
manuscript
sbb
provid
ebola
gp
protein
contribut
manuscript
write
spr
supervis
ebov
minigenom
replic
assay
contribut
experiment
design
manuscript
write
shh
supervis
project
contribut
experiment
design
manuscript
write
ks
supervis
manag
project
includ
experiment
design
data
analysi
manuscript
write
provid
fund
project
figur
catb
preincub
cathepsin
b
specif
inhibitor
amp
reaction
buffer
min
addit
catb
substrat
peptid
zargargamc
reaction
incub
room
temperatur
hr
fluoresc
gener
cleavag
catb
substrat
measur
p
p
twoway
anova
test
b
amp
inhibit
catb
intrins
enzymat
activ
reaction
perform
differ
concentr
amp
serial
dilut
c
reaction
perform
except
use
catl
substrat
peptid
zpheargamc
p
twoway
anova
test
